remission

AB0965 EXTRA-AXIAL MANIFESTATIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: THE COURSE AND RESPONSE TO THERAPEUTIC AGENTS
A. Yilmaz, E. Bektaş, A. Canik, B. Artim-Esen, M. Inanc, A. Gül, Y. Yalçinkaya

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 1701-1702; DOI: 10.1136/annrheumdis-2023-eular.5700
AB1134 IMPACT OF INFLAMMATORY BOWEL DISEASE ON DAPSA REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS: A PROPENSITY SCORE-MATCHED RETROSPECTIVE ANALYSIS OF “CROSS” MULTIDISCIPLINARY PROJECT PATIENTS’.
M. Giannotta, V. Venerito, L. Pacello, M. B. Principi, C. Foti, A. Di Leo, F. Iannone

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 1797-1798; DOI: 10.1136/annrheumdis-2023-eular.1829
AB1146 PHYSICIAN ADHERENCE TO CLINICAL GUIDELINES IN RHEUMATOLOGY: CAN IT HELP PROVIDING EVIDENCE-BASED, STANDARDIZED CLINICAL DECISIONS.
Y. El Miedany, N. Kamel, M. H. Abu-Zaid, A. Abdel-Nasser, M. A. Mortada, W. Hassan, S. A. Mahran, H. Sayed, R. Abdel Khalek, N. Fouad, S. A. A. Tabra, W. Elwakil, S. Saber

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 1803; DOI: 10.1136/annrheumdis-2023-eular.1090
OP0053 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
M. Hassanien, A. Moshrif, H. Hetta

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 34-35; DOI: 10.1136/annrheumdis-2023-eular.895
POS0322 CLINICAL DISEASE ACTIVITY INDEX REMISSION IN RHEUMATOID ARTHRITIS AT 6 MONTHS IS ASSOCIATED WITH HIGHER FREQUENCY OF TRANSITIONAL B CELLS AT DIAGNOSIS
S. Mcgrath, B. Sundbeck, C. Jonsson, K. Thorarinsdottir, A. Camponeschi, M. Gatto, A. K. H. Ekwall, R. Van Vollenhoven, A. Rudin, I. L. Mårtensson, I. Gjertsson

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 405-406; DOI: 10.1136/annrheumdis-2023-eular.2283
POS0596-HPR GOUT PATIENTS’ PERSPECTIVE ON CONTINUATION OR DISCONTINUATION OF URATE-LOWERING THERAPY WHEN REMISSION HAS BEEN ACHIEVED: A MIXED METHODS STUDY
I. R. Peeters, F. Veenstra, J. E. Vriezekolk, C. Van den Ende, A. Den Broeder, S. A. C. Wanten, N. Van Herwaarden, L. M. Verhoef, M. Flendrie

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 569; DOI: 10.1136/annrheumdis-2023-eular.1279
POS1603 TREAT-TO-TARGET STRATEGIES IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA: A SYSTEMATIC LITERATURE REVIEW INFORMING AN INTERNATIONAL TASKFORCE
E. Hysa, M. Bond, L. Ehlers, D. Camellino, L. Falzon, C. Dejaco, F. Buttgereit, D. Aletaha, A. Kerschbaumer

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 658; DOI: 10.1136/annrheumdis-2023-eular.3193
POS0843 DISTINCT TREATMENT RESPONSES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING FILGOTINIB 200 MG OVER 12 MONTHS: A POST HOC ANALYSIS OF FINCH 1
P. C. Taylor, Y. Tanaka, E. Aiello, T. Debray, C. Watson, K. Harris, G. R. Burmester

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 720-721; DOI: 10.1136/annrheumdis-2023-eular.1318
POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY
M. H. Buch, D. Aletaha, R. Caporali, B. Combe, H. Schulze-Koops, J. E. Gottenberg, Y. Tanaka, R. Blanco, T. Takeuchi, E. V. Ekoka Omoruyi, K. Van Beneden, V. Rajendran, C. Watson, F. De Leonardis, P. Emery

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 729-730; DOI: 10.1136/annrheumdis-2023-eular.3572
OP0123 AUTOANTIBODIES TO JOINT-RELATED PROTEINS PREDICT REMISSION IN NEW ONSET RA WITH HIGH SPECIFICITY
M. Leu Agelii, O. Sareila, E. Lönnblom, K. Forslind, I. Hafström, M. Andersson, A. Kastbom, C. Sjowall, L. T. H. Jacobsson, J. Kihlberg, R. Holmdahl, I. Gjertsson

Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 80; DOI: 10.1136/annrheumdis-2023-eular.5398

Main menu

remission

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

remission

Pages